Merck & Co’s experimental fixed-dose combination of favezelimab and pembrolizumab failed to improve overall survival in patients with pretreated microsatellite-stable metastatic colorectal cancer (mCRC) in a Phase 3 study. The study, KEYFORM-007, did not meet its primary endpoint, leading to a setback for the company. Despite this, Merck’s Keytruda continues to secure approvals for other cancer types.